NICE backs Aubagio

The U.K.'s NICE issued a Aubagio teriflunomide from the Genzyme Corp. unit of Sanofi (Euronext:SAN; NYSE:SNY) to treat active relapsing-remitting multiple sclerosis (RRMS) in patients who do not have highly active or rapidly evolving severe RRMS. The recommendation is contingent on Genzyme providing Aubagio at an undisclosed discount under a patient access scheme. In September, NICE had requested more information from Genzyme, including revised cost-effectiveness estimates reflecting U.K. clinical practice (see BioCentury Extra, Sept. 17). ...